Jeremy Tomlinson is a Professor of Metabolic Endocrinology and consultant endocrinologist based in the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital.

His research investigates the causes and treatment of human metabolic diseases including obesity, insulin resistance and non-alcoholic fatty liver disease (NAFLD). NAFLD represents one of the biggest health challenges that we face; it is a common condition, estimated to be present in up to 30% of the population and is associated with increased risk of heart disease, stokes as well as liver cirrhosis. His work in NALFD has explored the use of novel markers to stage disease severity without the need for liver biopsy as well as investigating the benefits of treating the condition with of agents including glucagon-lie peptide 1 analogues. In addition, he has helped to demonstrate the clinical benefits of a multi-disciplinary approach to the treatment the condition. Alongside his work in NAFLD, he also has a long-standing research interest in the role of steroid hormones in the development of metabolic conditions. More recently his work has looked at the prevalence of the adverse metabolic effects of prescribed steroids as well as trialling agents to limit their side effect profile. As part of his role as a consultant endocrinologist he runs general and specialized endocrine clinics at the Churchill hospital.